How We Use Corticosteroids in Immune Thrombocytopenia
ABSTRACT Introduction Corticosteroids remain an important first‐line treatment for immune thrombocytopenia (ITP), but their benefits are accompanied by substantial toxicities across various body systems. Their use should therefore be individualised and time‐limited. Methods We synthesise current guidance and published evidence concerning the selection of patients for corticosteroids treatment, choice of regimen, prevention and monitoring of treatment‐related toxicity, recognition of response and non‐response, and structured tapering and discontinuation in adults with ITP. Results Corticosteroids should be avoided when observation is clinically appropriate and, when prescribed, should have a pre‐defined indication, haemostatic control target, expected time to response and stopping date. Accepted first‐line regimens include prednisolone at 1–2 mg/kg/day, generally capped at 60–80 mg daily, or high‐dose dexamethasone at 40 mg daily for 4 days. A platelet count exceeding 50 × 10 9 /L within 5–7 days generally identifies an early responder, although a lower count may be adequate when bleeding has resolved and haemostatic safety has been achieved. Responders receiving prednisolone should proceed to dose reduction and complete discontinuation within approximately 6–8 weeks. Patients without an adequate early response should have prednisolone tapered over approximately 2 weeks and with prompt consideration of an alternative or steroid‐sparing treatment rather than prolonged dose escalation. Treatment extending beyond 3 weeks, particularly at doses exceeding 5 mg/day of prednisolone equivalent, may confer a risk of hypothalamic‐pituitary‐adrenal axis suppression and require a more structured taper. Conclusions Clinicians must balance the therapeutic goals of corticosteroids against the risk of toxicities from their use. The objective of corticosteroid therapy in ITP is to achieve haemostatic safety rather than to elevate or normalise the platelet count. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission
Authors
- Mervyn Morgan
- Drew Provan (ORCID: https://orcid.org/0000-0002-5110-8455)
- Jecko V. Thachil (ORCID: https://orcid.org/0000-0001-7218-0993)
- Gerard Gurumurthy (ORCID: https://orcid.org/0009-0008-0808-8779)
Institutions
- Queen Mary University of London (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- University of Manchester (GB)
- Queen Elizabeth Hospital King's Lynn NHS Foundation Trust (GB)
- Addenbrooke's Hospital (GB)
- Blizard Institute (GB)
Publication Details
- Journal
- eJHaem
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1002/jha2.70460
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00